PDGFRA and gastrointestinal stromal tumor: However, patients with unresectable/metastatic PDGFRA D842V-mutant GIST have a poor prognosis because imatinib and other approved TKIs lack activity against PDGFRA D842V-mutant kinases [3, 11, 12].